Pathophysiology and therapeutic modification of thrombin generation in patients with coronary artery disease

European Journal of Pharmacology

Volumn 402, Issue 1-2, 2000, Pages 1-10

  Pothula, Anitha ^a   Serebruany, Victor L ^a   Gurbel, Paula ^a   McKenzie, Marcus E ^a   Atar, Dan ^b  

^a SINAI HOSPITAL OF BALTIMORE   (United States)

^b Rigshospitalet   (Denmark)

Author keywords

(Human); Coagulation; Coronary artery disease; Thrombin

Indexed keywords

3 [[4 [4 (AMINOIMINOMETHYL)PHENYL] 2 THIAZOLYL](1 CARBOXYMETHYL 4 PIPERIDINYL)AMINO]PROPIONIC ACID; ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; DALTEPARIN; DIPYRIDAMOLE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; ORBOFIBAN; SIBRAFIBAN; SULFINPYRAZONE; TICLOPIDINE; WARFARIN; XEMILOFIBAN;

ANTICOAGULANT THERAPY; BLEEDING; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; HEART INFARCTION; HUMAN; PRIORITY JOURNAL; REVIEW; THROMBOCYTE ACTIVATION; THROMBOGENESIS; THROMBOSIS; UNSTABLE ANGINA PECTORIS;

CORONARY DISEASE; HUMANS; THROMBIN;

EID: 0034683182     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00440-4     Document Type: Review

References (119)

1. Altieri D.C., Edgington T.S. The saturable high affinity association of factor Xa to ADP-stimulated monocytes defines a novel function of the MAC-1 receptor. J. Biol. Chem. 263:1988;7007-7015.
2. Altieri D.C., Morrissey J.H., Edgington T.S. Adhesive receptor MAC-1 coordinates the activation of factor Xa on stimulated cells on monocytic and myeloid differentiation: an alternative initiation of the coagulation protease cascade. Proc. Natl. Acad. Sci. U. S. A. 56:1988;7462-7466.
3. Amiral J., Vissac A.M., Mimilla F., Grosley B. Assay of blood activation by measurement of ATIII-serine esterases complexes(ATM) using a specific mono clonal antibody 4C9. Thromb. Haemostasis. 62:1989;479-483.
4. Collaborative overview of randomized trials of antiplatelet therapy: Part I. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Br. Med. J. 308:1994;81-106.
5. Asinger R.W., Mikell F.L., Elsperger J., Hodges M. Incidence of left-ventricular thrombosis after acute transmural myocardial infarction. N. Engl. J. Med. 305:1981;297-302.
6. A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. J. Am. Med. Assoc. 243:1980;661-669.
7. Barrowcliffe T.W., Thomas D.P. Heparin and low molecule heparin. Bloom A.L., Forbes C.D., Thomas D.P., Tiddenham E.G.C. Haemostasis and Thrombosis. 1983;1417-1438 Churchill Livingstone, Edinburgh.
8. Bashour T.T., Myler R.K., Andreae G.E., Stertzer S.H., Clark D.A., Ryan C.J. Current concepts in unstable myocardial ischemia. Am. Heart J. 115:1988;850-861.
9. Bevers E.M., Comfuris P., Van Rijn J.L.M.L., Henker C., Zwaal R.F. Generation of prothrombin-converting activity and the exposure of phosphatidyl serine at the outer surface of platelets. Eur. J. Biochem. 122:1982;429-436.
10. Bevers E.M., Comfurius P., Zwaal R.F. Changes in membrane phospholipid distribution during platelet activation. Biochim. Biophys. Acta. 736:1983;57-66.
11. Bevers E.M., Comfuris P., Zwaal R.F. Mechanisms involved in platelets procoagulant response. Authi K.S.et al. Mechanism of Platelet Activation and Control. 1994;195-207 Plenum.
12. Bloomal A. The release of thrombin from fibrin by fibrinolysis. Br. J. Haematol. 8:1962;129-133.
13. Breddin K., Loew D., Lechner K., Uberla K., Walter E. Secondary prevention of myocardial infarction: a comparison of acetylsalicylic acid, placebo and phenprocoumon. Hemostasis. 9:1980;325-344.
14. Cairns J.A., Gent M., Singer J., Finnie K.J., Froggatt G.M., Holder D.A., Jablonsky G., Kostuk W.J., Melendez L.J., Myers M.G. Aspirin, sulfinprazone, or both in unstable angina: results of a Canadian multicenter trial. N. Engl. J. Med. 313:1985;1369-1375.
15. Chesebro J.H., Webster M.W., Zoldhelyi P., Roche P.C., Badimon L., Badimon J.J. Anti thrombin therapy and progression of coronary artery disease. Anti platelet versus anti thrombins. Circulation. 86:1982;III-100-111.
16. Chew D.P., Bhatt D.L., Topol E.J. Increased mortality with oral glycoprotein IIb/IIIa antagonists: a pooled analysis of the large scale oral glycoprotein IIb/IIIa trials. J. Am. Coll. Cardiol. 35:2000;393A-399A.
17. Cohen M., Adams P.C., Parry G., Xiong J., Chamberlain D., Wieczorec I. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in non prior aspirin users. Primary end points analysis from the ATACS Trial. Circulation. vol. 89:1994;81-88 Antithrombotic Therapy in Acute Coronary Syndromes Research Group.
18. Davies M.J., Thomas A.C. Plaque fissuring - the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br. Heart J. 53:1985;363-373.
19. Drapkin A., Merskey C. Anticoagulant therapy after acute myocardial infarction. J. Am. Med. Assoc. 222:1972;541-548.
20. Elwood P.C., Sweetnam P.M. Aspirin and secondary mortality after myocardial infarction. Lancet. 2:1979;1313-1315.
21. Elwood P.C., Cochrane A.L., Burr M.L., Sweetnam P.M., Williams G., Welsby E., Hughes S.J., Renton R. A randomized controlled trial of acetysalicylic acid in the secondary prevention of mortality from myocardial infarction. Br. Med. J. 1:1974;436-440.
22. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization. Circulation. 71:1985;699-708.
23. Falsiani M., Gori A.M., Fedi S., Chiarugi L., Simonetti I., Dabizzi R.P., Prisco D., Pepe G., Abbate R., Gensini G.F., Neri Serneri G.G. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischemic heart disease patients. Thromb. Haemostasis. 79:1998;495-499.
24. Fitzsimmons C., Proudfoot D., Bowyer D.E. Monocyte prostaglandins inhibit procollagen secretion by human vascular smooth muscle cells: implications for plaque stability. Atherosclerosis. 142:1999;287-293.
25. Flugelman M.Y., Virmani R., Correa T., Yu Z.X., Farb A., Leon M.B., Elami A., Fu Y.M., Casscells W., Epstein S.E. Smooth muscle cell abundance and fibroblast growth factors in coronary lesions of patients with nonfatal unstable angina. A clue to the mechanism of transformation from the stable to the unstable clinical state. Circulation. 88:1993;2493-2500.
26. Francis C.W., Markham R.E.Jr., Barlow G.H., Florack T.M., Dobrzynski D.M., Marader V.J. Thrombin activity of fibrin thrombi and soluble plasmic derivatives. J. Lab. Clin. Med. 102:1983;220-230.
27. Low-molecular-weight heparin during instability in coronary artery disease. Lancet. 347:1996;561-568.
28. Fujimoto T., Fujimura K., Kuramoto A. Electrophysiological evidence that glycoprotein IIb/IIIa complex is involved in calcium channel activation on human platelet plasma membrane. J. Biol. Chem. 266:1991;16370-16375.
29. Fuster V., Lewis A. Conner memorial lecture. Mechanisms leading to myocardial infarction: Insights from studies of vascular biology. Circulation. 90:1994;2126-2146.
30. Fuster V., Badimon L., Badimon J.J., Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N. Engl. J. Med. 326:1992;310-318.
31. Gallino A., Haeberli A., Hess T., Mombelli G., Straub P.W. Fibrin formation and platelet aggregation in patients with acute myocardial infarction: effect of intravenous and subcutaneous low dose heparin. Am. Heart J. 112:1986;285-290.
32. Long-term effects of intravenous thrombolysis in acute myocardial infarction. Lancet. 2:1987;871-874.
33. A factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet. 336:1990;65-71.
34. Gold H.K., Torres F., Garabedian H., Werner W., Jang I., Khan A., Hagstrom J., Yasuda T., Leinbach R., Newell J. Evidence for a rebound coagulation phenomenon after cessation of a 4-h infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J. Am. Coll. Cardiol. 21:1993;139-147.
35. Gruber A., Pal A., Kiss R.G., Sas G., Griffin J.H. Generation of activated protein C during thrombolysis. Lancet. 342:1993;1275-1276.
36. Gurfinkel E.P., Manos E.J., Mejail R.I., Cerda N.A., Duronto E.A., Garcia C.N., Daroca A.M., Mautner B. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J. Am. Coll. Cardiol. 26:1995;313-318.
37. Hawiger J. Formation and regulation of platelet and fibrin hemostatic plug. Hum. Pathol. 18:1987;111-132.
38. Herault J.P., Perou V., Savi P., Bernat A., Herbert J.M. Effect of SR121566A, a potent GPIIb/IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo. Thromb. Haemostasis. 79:1998;383-388.
39. Hirsh J., Levine M.N. Low molecular weight heparin. Blood. 79:1992;1-17.
40. Hoffmann P., Bernat A., Savi P., Herbert J.M. Prevention of thrombosis and enhancement of thrombolysis by SR 121787, a glycoprotein IIb/IIIa antagonist. J. Pharmacol. Exp. Ther. 286:1998;670-675.
41. Hoffmeister H.M., Jur M., Wendel H.P., Heller W., Seipel L. Alterations of coagulation and fibrinolytic and kallikrein-kinin systems in acute and post acute phases in patients with unstable angina pectoris. Circulation. 91:1985;2520-2527.
42. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither in 17,187 cases of suspected acute myocardial infarction: ISIS 2. Lancet. 2:1988;349-360.
43. ISIS-3: a randomized comparison of streptokinase versus tissue plasminogen activator versus anistreplase and of aspirin plus heparin versus heparin alone among 41,299 cases of suspected acute myocardial infarction. Lancet. 1:1992;753-770.
44. Julian D.G., Chamberlain D.A., Pocock S.J. A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER study): a multicentre unblinded randomised clinical trial. Br. Med. J. 313:1996;1429-1431.
45. Kereiakes D.J., Kleiman N.S., Ferguson J.J., Masud A.R., Broderick T.M., Abbottsmith C.W., Runyon J.P., Anderson L.C., Anders R.J., Dreiling R.J., Hantsbarger G.L., Bryzinski B., Topol E.J. Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial. Circulation. 98:1998;1268-1278.
46. Kienast J., Thompson S.G., Raskino C., Pelzer H., Fechtrup C., Ostermann H., van de Loo J. Prothrombin activation fragment 1+2 and thrombin antithrombin III complexes in patients with angina pectoris: relation to the presence and severity of coronary atherosclerosis. Thromb. Haemostasis. 70:1993;550-553.
47. Kong D.F., Califf R.M., Miller D.P. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation. 98:1998;2829-2835.
48. Lee C.D., Mann K.G. Activation/inactivation of human factor V by plasmin. Blood. 73(1):1989;185-190.
49. Lewis H.D. Jr., Davis J.W., Archibald D.G., Steinke W.E., Smitherman T.C., Doherty J.E. III, Schnaper H.W., LeWinter M.M., Linares E., Pouget J.M., Sabharwal S.C., Chesler E., DeMots H. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration cooperative study. N. Engl. J. Med. 309:1983;396-403.
50. Lindahl B., Venge P., Wallentin L. Troponin-T identifies patients with unstable coronary artery disease who benefit from long term antithrombotic protection. J. Am. Coll. Cardiol. 29:1997;43-48.
51. Lindhot T., Blezer R., Hemker H.C. The anticoagulant mechanism of action of recombinant Hirudin (CGP 39393) in plasma. Thromb. Haemostasis. 64:1990;464-468.
52. Livingstone E.R., Fisher C.A., Bibidakis E.J., Pathak A.S., Todd B.A., Furukawa S., McClurken J.B., Addonizio V.P., Jeevanandam V. Increased activation of the coagulation and fibrinolytic systems leads to hemorrhagic complications during left ventricular assist implantation. Circulation. 94:1996;II227-II234. (9 Suppl).
53. Loeliger E.A., Hemker H.C. A double-blind trial of long-term anticoagulant treatment after myocardial infarction. Acta Med. Scand. 182:1967;549-566.
54. Marciniak E., Gockerman J. Heparin-induced decrease in circulating antithrombin-III. Lancet. 2:1997;581-584.
55. Mark D.B., Braunwald E. Medical management of unstable angina. Fuster V., Ross R., Topol E.J. Atherosclerosis and Coronary Artery Disease. 1995;1315-1326 Lippincott-Raven, Philadelphia, PA.
56. Merlini P.A., Ardissino D., Bauer K.A., Oltrona L., Pezzano A., Bottaso B., Rosenberg R.D., Mannucci P.M. Persistent thrombin generation during heparin therapy in patients with coronary acute coronary syndromes. Arterioscler., Thromb., Vasc. Biol. 17:1997;1325-1330.
57. Meuwissen O.J.A.T., Vervoorn A.C., Cohen O., Jordan F.L., Nelemans F.A. Double blind trial of long-term anticoagulation after infarction. Acta Med. Scand. 186:1969;361-368.
58. Mombelli G., Hof I., Haeberli A., Straub P.W. Effect of heparin on plama fibrinopeptide A in patients with acute myocardial infarction. Circulation. 69:1984;684-689.
59. Nemerson Y. Tissue factor and hemostasis. Blood. 71:1988;1-8.
60. Neri Serneri G.G., Abbate R., Gensini G.H., Gori A.M., Attansio M., Martini F. Monocyte activation and increased procoagulant activity in unstable angina. Lancet. 336:1990;1444-1445.
61. Neri Serneri G.G., Gensini G., Poggesi L., Trotta F., Modesti P.A., Boddi M., Ieri A., Margheri M., Casolo G.C., Bini M., Rostagno C., Carnovali M., Abbate R. Effect of heparin, aspirin, or alteplase in reduction of myocardial ischemia in refractory unstable angina. Lancet. 335:1990;615-618.
62. Neri Serneri G.G., Abbate R., Gori A.M., Attanasio M., Martini F., Giusti B., Dabizzi P., Poggesi L., Modesti P.A., Trotta F., Rostagno C., Boddi M., Gensini G.F. Transient intermittent lymphocyte activation is responsible for the instability of angina. Circulation. 486:1992;790-797.
63. Nurden A.T. Human platelet membrane glycoproteins. Bloom A.L., Forbes C.D., Thomas D.P., Tuddenham E.G.D. Haemostasis and Thrombosis. 1994;115-165 Churchill Livingstone, Edinburgh.
64. Ofosu F.A., Sie P., Modi G.J., Fernandez F., Buchanan M.R., Blajchman M.A., Boneu B., Hirsh J. The inhibition of thrombin-dependent positive-feedback reactions is critical to the expression of the anticoagulant effect of heparin. Biochem. J. 243:1987;579-588.
65. Ofosu F.A., Hirsh J., Esmon C.T., Modi G.J., Smith L.M., Anvari N., Buchanan M.R., Fenton J.W., Blajchman M.A. Unfractionated heparin inhibits thrombin catalyzed amplification reactions of coagulation more efficiently than those catalyzed by factor Xa. Biochem. J. 257:1989;143-150.
66. Ohman E.M., Kleiman N.S., Gacioch G., Worley S.J., Navetta F.I., Talley J.D., Anderson H.V., Ellis S.G., Cohen M.D., Spriggs D., Miller M., Kereiakes D., Yakubov S., Kitt M.M., Topol E.J. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. Circulation. vol. 95:1997;846-854 IMPACT-AMI Investigators.
67. Peoe G., Giusti B., Attanasio M., Gori A.M., Comeglio P., Martini F., Gensini G.H., Abbate R., Neri Serneri G.G. Tissue factor and plasminogen activator inhibitor type 2 expression in human stimulated monocytes is inhibited by heparin. Semin. Thromb. Hemostasis. 23:1997;135-141.
68. Rao A.K., Sun L., Chesebro J.H., Fuster V., Harrington R.A., Schwartz D., Gallo P., Matos D., Topol E.J. Distinct effects of recombinant desulfatohirudin (revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina. Circulation. 94:1996;2389-2395.
69. Rasmanis G., Vesterqvist O., Green M., Edhag O., Henriksson P. Evidence of increased platelet activation after thrombolysis in patients with acute myocardial infarction. Br. Heart J. 68:1992;374-376.
70. Reverter J.C., Beguin S., Kessels R., Hemker H.C., Coller B.S. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. J. Clin. Invest. 98:1996;863-874.
71. Rosenberg R.D. Actions and interactions of antithrombin and heparin. N. Engl. J. Med. 292:1975;146-151.
72. Rosing J., Trans G., Govers-Riemslag J.W., Zwaal R.F., Hemker H.C. The role of phospholipids and factor Va in the prothrombinase complex. J. Biol. Chem. 255:1980;274-283.
73. Sandset P.M., Abildgaard U., Larsen M.L. Heparin induces release of extrinsic pathway inhibitor[EPI]. Thromb. Res. 50:1988;803-813.
74. Sandset P.M., Sirnes P.A., Abildgaard U. Factor VII and extrinsic pathway inhibitor in acute coronary disease. Br. J. Haematol. 72:1989;4391-4396.
75. Savi P., Badorc A., Lale A., Bordes M.F., Bornia J., Labouret C., Bernat A., De Cointet P., Hoffmann P., Maffrand J.P., Herbert J.M. SR 121787, a new orally active fibrinogen receptor antagonist. Thromb. Haemostasis. 80:1998;469-476.
76. Randomized controlled trial of subcutaneous calcium-heparin in acute myocardial infarction. The SCATI (studio sulla calciparina nell' Angina e nella trombosi ventricolare nell' infarto miocardico). Lancet. 2:1989;182-186.
77. Seitz R., Blanke H., Pratorius G., Strauer B.E., Egbring R. Increased thrombin activity during thrombolysis. Thromb. Haemostasis. 59:1988;541-542.
78. Simon D.I., Xu H., Ortlepp S., Rogers C., Rao N.K. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler., Thromb., Vasc. Biol. 17:1997;528-535.
79. Sims P.J., Wiedmer T. The response of human platelets to activated components of the complement system. Immunol. Today. 12(9):1991;338-342.
80. Smeets E.F., Comfurius P., Bevers E.M., Zwaal R.F. Calcium-induced transbilayer scrambling of fluorescent phospholipid analogs in platelets and erythrocytes. Biochim. Biophys. Acta. 1195:1994;281-286.
81. Smith P., Arnesen H., Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N. Engl. J. Med. 323:1990;147-152.
82. Soerensen O.H., Friis T., Joergensen A.W., Joergensen M.B., Nissen N.I. Anticoagulant treatment of acute coronary thrombosis. Acta Med. Scand. 185:1969;65-72.
83. Soncini M., Casazza F., Mattioli R., Bonfardeci C., Motta A., Cimminiello C. Hypercoagulability and chronic atrial fibrillation: the role of markers of thrombin generation. Minerva Med. 88:1997;501-505.
84. Stone S.R., Hofsteenge J. Kinetics of the inhibition of thrombin by hirudin. Biochemistry. 25:1986;4622-4628.
85. Szczeklik A., Dropinski J., Radwan J., Krzanowski M. Persistent generation of thrombin after acute myocardial infarction. Arterioscler. Thromb. 12:1992;548-553.
86. Teitel J.M., Rosenberg R.D. Protection of factor Xa from neutralization by the heparin-antithrombin complex. J. Clin. Invest. 71:1983;1383-1391.
87. Telford A.M., Wilson C. Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronay syndromes. Lancet. 1:1981;1225-1228.
88. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet. 343:1994;499-503.
89. Randomized placebo-controlled trials of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet. 349:1997;1429-1435.
90. Aspirin in coronary heart disease. J. Chronic Dis. 129:1976;625-642.
91. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N. Engl. J. Med. 330:1994;956-961.
92. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N. Engl. J. Med. 336:1997;1689-1696.
93. A controlled comparison of aspirin and oral anticoagulants in prevention of death af myocardial infarction. N. Engl. J. Med. 307:1982;701-709.
94. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N. Engl. J. Med. 329:1993;673-692.
95. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet. 349:1997;1422-1428.
96. International, randomized , controlled trial of lamifiban, a platelet glycoprotein IIb/IIIa inhibitor, heparin, or both in unstable angina. Circulation. 97:1998;2386-2395.
97. Persantine and aspirin in coronary heart disease. Circulation. 62:1980;449-461.
98. The platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N. Engl. J. Med. 338:1998;1488-1497.
99. Platelet receptor inhibition in ischemic syndrome management. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N. Engl. J. Med. 338:1998;1498-1505.
100. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. N. Engl. J. Med. 339:1998;436-443.
101. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 96:1997;1445-1453.
102. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable corinary artery disease. Lancet. 336:1990;827-830.
103. Theroux P., Ouimet H., Mc Cans J., Latour J.G., Joly P., Levy G., Pelletier E., Juneau M., Stasiak J., deGuise L.T. Aspirin, heparin or both to treat acute unstable angina. N. Engl. J. Med. 319:1988;1105-1111.
104. Theroux P., Waters D., Lam J., Juneau M., McCans J. Reactivation of unstable angina after discontinuation of heparin. N. Engl. J. Med. 327:1992;141-145.
105. Theroux P., Waters D., Qiu S., Mc Cans J., de Guise P., Juneau M. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation. 88:1993;2045-2048.
106. A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet. 2:1980;989-993.
107. Comparison of Sibrafiban with Aspirin for prevention of cardiovascular events after acute coronary syndromes. Lancet. 355:2000;337-345.
108. Van Dieijen G., Trans G., Rosing J., Hember H.C. The role of phopholipids and factor VIIIa in the activation of Bovine factor X. J. Biol. Chem. 256(7):1981;3433-3442.
109. Vanhoutte P.M. Endothelium-dependent responses in congestive heart failure. J. Mol. Cell. Cardiol. 28:1996;2233-2240.
110. Vanhoutte P.M. Endothelial dysfunction and atherosclerosis. Eur. Heart J. 18:1997;19-29. (Suppl E).
111. Varadi K., Philapitsch A., Santa T., Schwartz H.P. The effect of plasmin on protein C and activated protein C. Circulation. 86:1992;. I-736a.
112. Verstraete M.J., Chesebro J.H., Fuster V. Antithrombotic therapy. Fuster V., Ross R., Topol E.J. Atherosclerosis and Coronary Artery Disease. 1995;979-994 Lippincott-Raven, Philadelphia, PA.
113. Walsh P.M., Schmaier A.H. Platelet coagulation interactions. Coleman R.W., Hirsh J., Marder V.J., Salzman E.W. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 3rd edn. 1994;629-651 J.B. Lipincott, Philadelphia.
114. Weitz J.I., Hudoba M., Massel D., Maraganore J., Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J. Clin. Invest. 86:1990;385-391.
115. Wilcox J.N. Thrombotic mechanisms in atherosclerosis. Coron. Artery Dis. 5:1994;223-229.
116. Wilcox J.N., Smith K.M., Schwartz S.M., Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc. Natl. Acad. Sci. U. S. A. 86:1989;2839-2843.
117. Willerson J.T., Casscells W. Thrombin inhibitors in unstable angina; rebound or continuation of angina after argatroban withdrawal? J. Am. Coll. Cardiol. 21:1993;1048-1051.
118. Williamson P., Bevers E.M., Smeets E.F., Comfurius P., Schlegel R.A., Zwaal R.F. Continuous analysis of the mechanism of activated transbilayer lipid movement in platelets. Biochemistry. 34:1995;10448-10455.
119. Zhou Q., Zhao J., Stout J.G., Luhm R.A., Wiedmer T., Sims P.J. Molecular cloning of human plasma membrane phospholipid scramblase. A protein mediating transbilayer movement of plasma membrane phospholipids. J. Biol. Chem. 272:1997;18240-18244.